KR20230054419A - Glp-1 수용체 작용제 융합체를 인코딩하는 바이러스 벡터 및 고양이과의 대사 질환 치료에서 이의 용도 - Google Patents
Glp-1 수용체 작용제 융합체를 인코딩하는 바이러스 벡터 및 고양이과의 대사 질환 치료에서 이의 용도 Download PDFInfo
- Publication number
- KR20230054419A KR20230054419A KR1020237009389A KR20237009389A KR20230054419A KR 20230054419 A KR20230054419 A KR 20230054419A KR 1020237009389 A KR1020237009389 A KR 1020237009389A KR 20237009389 A KR20237009389 A KR 20237009389A KR 20230054419 A KR20230054419 A KR 20230054419A
- Authority
- KR
- South Korea
- Prior art keywords
- feline
- viral vector
- leu
- glp
- glu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/485—Exopeptidases (3.4.11-3.4.19)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
- C12Y304/14005—Dipeptidyl-peptidase IV (3.4.14.5)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063069492P | 2020-08-24 | 2020-08-24 | |
| US63/069,492 | 2020-08-24 | ||
| PCT/US2021/047403 WO2022046809A1 (en) | 2020-08-24 | 2021-08-24 | Viral vector encoding glp-1 receptor agonist fusions and uses thereof in treating metabolic diseases in felines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230054419A true KR20230054419A (ko) | 2023-04-24 |
Family
ID=80355670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237009389A Pending KR20230054419A (ko) | 2020-08-24 | 2021-08-24 | Glp-1 수용체 작용제 융합체를 인코딩하는 바이러스 벡터 및 고양이과의 대사 질환 치료에서 이의 용도 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230405150A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4199942A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2023539247A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230054419A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116390745A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021332232A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3190396A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022046809A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026039341A1 (en) | 2024-08-12 | 2026-02-19 | Akston Biosciences Corporation | Fc fusion protein therapeutics for companion animal obesity and methods of use |
| WO2026039359A1 (en) | 2024-08-12 | 2026-02-19 | Akston Biosciences Corporation | Fc fusion protein therapeutics for companion animal obesity and methods of use |
| WO2026039340A1 (en) | 2024-08-12 | 2026-02-19 | Akston Biosciences Corporation | Fc fusion protein therapeutics for companion animal obesity and methods of use |
| CN120005002B (zh) * | 2025-04-22 | 2025-07-25 | 西宝生物科技(上海)股份有限公司 | 一种glp-1类似物的生物发酵制备方法及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1724284T1 (sl) * | 2000-12-07 | 2009-12-31 | Lilly Co Eli | Glp-1 fuzijski proteini |
| CA2833623A1 (en) * | 2011-04-20 | 2012-10-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Aav mediated exendin-4 gene transfer to salivary glands to protect subjects from diabetes or obesity |
| WO2017024198A1 (en) * | 2015-08-06 | 2017-02-09 | The Trustees Of The University Of Pennsylvania | Glp-1 and use thereof in compositions for treating metabolic diseases |
| EP3481413A4 (en) * | 2016-07-08 | 2020-01-08 | Askgene Pharma, Inc. | FUSION PROTEIN WITH LEPTIN AND METHOD FOR THE PRODUCTION AND USE THEREOF |
| AU2018318440A1 (en) * | 2017-08-15 | 2020-02-13 | Kindred Biosciences, Inc. | IgG Fc variants for veterinary use |
| WO2020139984A1 (en) * | 2018-12-27 | 2020-07-02 | Kindred Biosciences, Inc. | Igg fc variants for veterinary use |
-
2021
- 2021-08-24 EP EP21862600.0A patent/EP4199942A4/en active Pending
- 2021-08-24 AU AU2021332232A patent/AU2021332232A1/en active Pending
- 2021-08-24 JP JP2023513299A patent/JP2023539247A/ja active Pending
- 2021-08-24 US US18/042,729 patent/US20230405150A1/en active Pending
- 2021-08-24 KR KR1020237009389A patent/KR20230054419A/ko active Pending
- 2021-08-24 CN CN202180072448.2A patent/CN116390745A/zh active Pending
- 2021-08-24 WO PCT/US2021/047403 patent/WO2022046809A1/en not_active Ceased
- 2021-08-24 CA CA3190396A patent/CA3190396A1/en active Pending
-
2026
- 2026-03-05 JP JP2026035302A patent/JP2026115041A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN116390745A (zh) | 2023-07-04 |
| AU2021332232A1 (en) | 2023-03-23 |
| CA3190396A1 (en) | 2022-03-03 |
| JP2026115041A (ja) | 2026-07-08 |
| JP2023539247A (ja) | 2023-09-13 |
| WO2022046809A1 (en) | 2022-03-03 |
| US20230405150A1 (en) | 2023-12-21 |
| EP4199942A1 (en) | 2023-06-28 |
| EP4199942A4 (en) | 2025-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6978407B2 (ja) | Glp−1及び代謝性疾患を治療するための組成物におけるその使用 | |
| CN116390745A (zh) | 编码glp-1受体激动剂融合体的病毒载体及其在治疗猫科动物代谢疾病中的用途 | |
| JP7840319B2 (ja) | Glp-1受容体アゴニスト融合物をコードするウイルスベクター及び代謝性疾患の治療におけるその使用 | |
| US20250171515A1 (en) | Aav vectors for delivery of glp-1 receptor agonist fusions | |
| US20250388926A1 (en) | Viral vector genome encoding an insulin fusion protein | |
| US20250186613A1 (en) | Viral vectors encoding glp-2 receptor agonist fusions and uses thereof in treating short bowel syndrome | |
| US20250186612A1 (en) | Viral vectors encoding parathyroid hormone fusions and uses thereof in treating hypoparathyroidism | |
| KR20230104136A (ko) | 조성물 및 이의 용도 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |